Feline Herpesvirus-1 Infection (Feline Viral Rhinotracheitis)

Feline herpesvirus-1 (FHV-1) infection, also known as feline viral rhinotracheitis (FVR), is a highly contagious, acute, and often recurrent viral disease of domestic and wild felids. It is caused by a double-stranded DNA virus belonging to the family Herpesviridae, subfamily Alphaherpesvirinae, genus Varicellovirus. The disease primarily affects the upper respiratory tract, conjunctiva, and cornea, leading to clinical signs such as serous to mucopurulent nasal discharge, sneezing, conjunctivitis, and corneal ulceration. FHV-1 is a major component of the feline upper respiratory disease complex (URDC), along with feline calicivirus (FCV) and other pathogens. The virus establishes lifelong latency in the trigeminal ganglia and other neural tissues, with periodic reactivation and shedding, especially during stress or immunosuppression. The disease can range from subclinical to severe, with fatal outcomes in kittens, immunocompromised cats, or those with concurrent infections. Systemic manifestations, such as pneumonia, hepatitis, and disseminated intravascular coagulation, are rare but can occur in severe cases, particularly in neonates. The infection is worldwide in distribution and is a significant cause of morbidity and mortality in shelters, catteries, and multi-cat households.

The primary causative agent is Felid alphaherpesvirus 1 (FHV-1), a member of the family Herpesviridae, subfamily Alphaherpesvirinae. The virus has a linear double-stranded DNA genome of approximately 126 kbp, encoding over 70 proteins, including glycoproteins involved in attachment, entry, and immune evasion. Key glycoproteins include gB, gC, gD, gE, gG, gH, gI, and gL, which mediate viral entry, cell-to-cell spread, and syncytia formation. FHV-1 is enveloped and labile in the environment, being inactivated by desiccation, heat (above 56°C for 5 minutes), and common disinfectants (e.g., bleach, quaternary ammonium compounds). Transmission occurs primarily via direct contact with infected ocular, nasal, or oral secretions, as well as fomites (food bowls, bedding, grooming tools) and aerosolized droplets over short distances. The virus replicates initially in the nasal mucosa, nasopharynx, tonsils, and conjunctival epithelium, causing lytic infection and necrosis. After primary infection, the virus establishes latency in the trigeminal ganglia, and to a lesser extent in other neural tissues, where it remains dormant. Reactivation can be triggered by stress, glucocorticoid administration, parturition, lactation, or concurrent illness, leading to viral shedding and clinical recrudescence. The incubation period is typically 2 to 6 days. FHV-1 is species-specific and does not infect humans or other domestic animals, although it can cause disease in other felids, including lions, tigers, and cheetahs.

FHV-1 infection is endemic worldwide in domestic cats (Felis catus) and other felids. Seroprevalence studies indicate that up to 90% of cats in multi-cat environments (shelters, catteries) are seropositive, while free-roaming cats have lower prevalence (30-50%). The virus is highly contagious, with a basic reproduction number (R0) estimated at 4-10 in susceptible populations. Kittens are most susceptible, with peak incidence between 4 to 12 weeks of age, especially after maternal antibody wanes. Breed predisposition is not well-established, but purebred cats in catteries may have higher infection rates due to overcrowding and stress. There is no sex predilection. The disease shows seasonal variation in temperate climates, with higher incidence in autumn and winter, possibly due to increased indoor crowding and reduced ventilation. In shelters, outbreaks are common, with up to 30-40% of cats developing clinical disease. The virus can survive in the environment for up to 18 hours on moist surfaces, but is rapidly inactivated by drying and disinfectants. Latently infected cats serve as the main reservoir, shedding virus intermittently, especially during stress. The economic impact is significant due to veterinary costs, treatment, and mortality in shelters and breeding facilities.

FHV-1 enters the host via the oronasal or conjunctival routes, attaching to host cell receptors (e.g., herpesvirus entry mediator A, nectin-1, and heparan sulfate proteoglycans) via viral glycoproteins. After fusion with the cell membrane, the nucleocapsid is transported to the nucleus, where viral DNA replication and transcription occur. The virus causes lytic infection of epithelial cells, leading to cell death, desquamation, and necrosis of the respiratory and conjunctival mucosa. This results in the characteristic clinical signs of sneezing, nasal discharge, and conjunctivitis. The virus also infects and replicates in the upper respiratory tract, including the nasal turbinates, nasopharynx, and tonsils, causing severe inflammation and secondary bacterial infection. The immune response involves both innate (interferons, natural killer cells) and adaptive (humoral and cell-mediated) mechanisms. However, FHV-1 has evolved immune evasion strategies, including downregulation of major histocompatibility complex (MHC) class I expression, inhibition of apoptosis, and modulation of cytokine responses. After primary infection, the virus travels via sensory nerve endings to the trigeminal ganglia, where it establishes latency. During latency, the viral genome persists as an episome, with limited gene expression. Reactivation leads to anterograde transport of virions back to the original site of infection, causing recurrent clinical signs and viral shedding. Systemic spread can occur in neonates or immunocompromised cats, leading to viremia and dissemination to visceral organs, causing hepatitis, pneumonia, and disseminated intravascular coagulation. Ocular involvement is common, with conjunctivitis and corneal ulceration due to viral replication in the corneal epithelium, leading to dendritic ulcers, which are pathognomonic. Chronic stromal keratitis may result from immune-mediated mechanisms.

Several intrinsic and extrinsic factors increase the risk and severity of FHV-1 infection. Intrinsic factors include age (kittens under 6 months are more susceptible), immune status (immunosuppression due to FIV, FeLV, or glucocorticoid therapy), genetic susceptibility (some breeds may have higher susceptibility, though not well-defined), and stress (which triggers reactivation). Extrinsic factors include overcrowding, poor ventilation, high humidity, poor sanitation, and inadequate nutrition. Concurrent infections with other respiratory pathogens (e.g., feline calicivirus, Bordetella bronchiseptica, Chlamydia felis, Mycoplasma spp.) can exacerbate clinical signs. Stressful events such as weaning, transportation, boarding, surgery, or introduction to a new environment can precipitate reactivation of latent virus. In shelters, high population density and high turnover rates facilitate transmission. Lack of vaccination or incomplete vaccination protocols increase susceptibility. Maternal antibody interference can reduce vaccine efficacy in kittens. Environmental factors such as low ambient temperature and high ammonia levels from urine can irritate the respiratory tract and predispose to secondary bacterial infections.

Clinical signs of FHV-1 infection vary depending on the age, immune status, and stage of infection. The incubation period is 2-6 days. In peracute cases, especially in kittens, there may be sudden death without premonitory signs. Acute infection is characterized by fever (103-105°F), depression, anorexia, and severe upper respiratory signs: frequent sneezing, serous nasal discharge that becomes mucopurulent due to secondary bacterial infection, conjunctivitis with chemosis, and ocular discharge. Cats often have a characteristic 'sneezing and snuffling' appearance. Oral ulceration is less common than with calicivirus but can occur on the tongue and hard palate. Corneal involvement is common, with dendritic ulcers (branching, linear erosions) visible on fluorescein staining. In severe cases, corneal ulcers may become geographic or indolent, leading to corneal perforation. Chronic infection can lead to chronic rhinosinusitis, with persistent nasal discharge, sneezing, and nasal congestion. Ocular sequelae include chronic conjunctivitis, corneal sequestrum, and eosinophilic keratitis. Systemic signs may include pneumonia, especially in kittens, with tachypnea, dyspnea, and crackles on auscultation. Dermatitis (ulcerative or vesicular) is rare but can occur, particularly on the face and trunk. In immunocompromised cats, viremia can lead to hepatitis, pancreatitis, and disseminated intravascular coagulation. Latent infection is asymptomatic, but reactivation causes recurrence of clinical signs, often milder and shorter in duration.

The differential diagnoses for FHV-1 infection include other causes of feline upper respiratory disease and ocular disease. Key differentials are: 1) Feline calicivirus (FCV) infection: causes similar respiratory signs but more prominent oral ulceration (tongue, hard palate), and less conjunctivitis and corneal ulceration. FCV can cause limping syndrome (transient lameness) and virulent systemic disease (VSD) with fever, edema, and cutaneous ulcers. 2) Chlamydia felis infection: primarily causes conjunctivitis, often unilateral, with mild respiratory signs. It responds to tetracyclines. 3) Bordetella bronchiseptica infection: causes coughing, nasal discharge, and pneumonia, especially in kittens. 4) Mycoplasma spp. infection: can cause conjunctivitis and respiratory signs, often secondary. 5) Feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) infections: cause immunosuppression and chronic secondary infections, but not primary respiratory signs. 6) Allergic rhinitis: chronic sneezing and nasal discharge without fever or ocular signs. 7) Nasopharyngeal polyps: cause stertor, nasal discharge, and dysphagia, visible on imaging. 8) Foreign body in nasal cavity: unilateral nasal discharge, sneezing, and pawing at the nose. 9) Fungal rhinitis (e.g., Cryptococcus, Aspergillus): chronic nasal discharge, often with facial swelling and destructive lesions on imaging. 10) Eosinophilic granuloma complex: can cause oral ulcers and skin lesions, but not respiratory signs. Definitive diagnosis is based on PCR, virus isolation, or immunofluorescence.

The diagnostic approach for suspected FHV-1 infection begins with a thorough history and physical examination, focusing on respiratory and ocular signs. A complete blood count (CBC), serum biochemistry, and urinalysis are recommended to assess overall health and rule out systemic disease. In acute cases, a presumptive diagnosis can be made based on typical clinical signs, especially dendritic corneal ulcers. For confirmation, polymerase chain reaction (PCR) on conjunctival or oropharyngeal swabs is the most sensitive and specific test, detecting viral DNA. PCR can be positive during acute infection and for up to 3 weeks after, but false negatives can occur if sampling is not performed during active shedding. Virus isolation is also possible but requires specialized cell culture and is less commonly used. Immunofluorescence or immunoperoxidase staining of conjunctival smears can detect viral antigens. Serology (antibody titers) is not useful for diagnosis of acute infection due to widespread seropositivity and the presence of maternal antibodies in kittens. In chronic cases, imaging (radiography, CT) of the nasal cavity may be indicated to rule out other causes of chronic rhinitis, such as fungal infection or neoplasia. Rhinoscopy and biopsy may be necessary for histopathology and PCR. For ocular disease, fluorescein staining is essential to detect corneal ulcers. In cases of suspected systemic involvement, thoracic radiographs and abdominal ultrasound may be performed. A stepwise algorithm: 1) Clinical suspicion based on signs; 2) Fluorescein stain to identify dendritic ulcers; 3) PCR on conjunctival and oropharyngeal swabs; 4) If PCR negative but high suspicion, repeat PCR in 3-5 days or perform virus isolation; 5) In chronic cases, advanced imaging and biopsy.

Hematology: In acute FHV-1 infection, the CBC may show mild leukopenia (lymphopenia and neutropenia) due to viral-induced immunosuppression, followed by leukocytosis with a left shift if secondary bacterial infection occurs. Mild anemia may be present in chronic cases. Serum biochemistry: Typically within normal limits, but may show mild elevations in liver enzymes (ALT, AST) if hepatitis occurs. In severe systemic disease, azotemia and electrolyte imbalances may occur due to dehydration. Urinalysis: Usually unremarkable. Blood gas analysis: May show respiratory acidosis if pneumonia is severe. Specific biomarkers: Feline alpha-1 acid glycoprotein (AGP) may be elevated as an acute-phase protein. Serology: Antibody titers (IgG, IgM) can be measured, but are not diagnostic for acute infection. PCR: Detection of FHV-1 DNA in conjunctival, nasal, or oropharyngeal swabs is the gold standard. Quantitative PCR (qPCR) can provide viral load, which correlates with disease severity. Virus isolation: Can be performed on swabs, but is time-consuming and less sensitive than PCR. Immunofluorescence: Direct fluorescent antibody testing on conjunctival smears can detect viral antigens, but sensitivity is lower than PCR.

Radiography: Thoracic radiographs may reveal interstitial or alveolar patterns in cases of pneumonia, especially in kittens. Skull radiographs may show increased opacity in the nasal cavity due to turbinate destruction or accumulation of exudate in chronic rhinitis. Ultrasonography: Not routinely used for FHV-1, but abdominal ultrasound may be helpful if systemic involvement is suspected (e.g., hepatomegaly, pancreatitis). Computed Tomography (CT): CT of the nasal cavity is valuable in chronic rhinitis to assess turbinate lysis, soft tissue masses, and rule out neoplasia or fungal granulomas. CT can also identify orbital involvement in severe ocular disease. Magnetic Resonance Imaging (MRI): MRI provides superior soft tissue contrast and is useful for evaluating the brain if encephalitis is suspected (rare). Endoscopy: Rhinoscopy allows direct visualization of the nasal mucosa, collection of biopsies, and flushing of exudate. It is particularly useful in chronic cases to rule out foreign bodies, polyps, or neoplasia. Fluoroscopy: Not commonly used. Echocardiography: Not indicated unless cardiac disease is suspected.

Cytology: Conjunctival scrapings or impression smears may show epithelial cells with intranuclear inclusion bodies (Cowdry type A) in acute infection, but sensitivity is low. In chronic cases, cytology of nasal exudate may reveal neutrophils and bacteria. Histopathology: Biopsy of nasal mucosa or conjunctiva may show epithelial necrosis, ulceration, and inflammation with mononuclear cell infiltration. Intranuclear inclusion bodies may be seen in early stages. In chronic rhinitis, there is often lymphoplasmacytic inflammation, fibrosis, and turbinate destruction. In cases of eosinophilic keratitis, histopathology shows eosinophilic infiltration of the cornea. Special stains (e.g., immunohistochemistry) can detect viral antigens in tissue sections.

Treatment of FHV-1 infection is primarily supportive, as there is no specific antiviral cure. The goals are to control clinical signs, prevent secondary bacterial infections, and reduce viral shedding. Emergency stabilization: In severe cases, especially kittens, hospitalization may be required for fluid therapy, nutritional support, and oxygen therapy. Fluid resuscitation: Use balanced crystalloids (e.g., Lactated Ringer's solution) at maintenance rates (40-60 ml/kg/day) or higher if dehydrated. Correct electrolyte imbalances. Nutritional support: If anorexic, place a nasoesophageal or esophagostomy tube for feeding a high-quality diet. Primary medical therapy: Antiviral drugs are used, though efficacy is variable. Famciclovir is the most commonly used antiviral in cats, at a dose of 40-90 mg/kg PO q8h for 7-14 days. It is a prodrug that converts to penciclovir, which inhibits viral DNA polymerase. Other antivirals include topical cidofovir (0.5% ophthalmic solution) for ocular disease, applied twice daily. Ganciclovir and idoxuridine are also used topically. Lysine supplementation (250-500 mg/cat PO q12h) is controversial but may reduce viral replication by antagonizing arginine. Supportive care: Use a humidifier or nebulization with saline to soothe the respiratory tract. Gently clean nasal and ocular discharges with warm saline. Topical ophthalmic antibiotics (e.g., oxytetracycline, erythromycin) are indicated if corneal ulceration is present to prevent secondary bacterial infection. Systemic antibiotics (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h, or doxycycline 5-10 mg/kg PO q12h) are used if secondary bacterial infection is suspected. Anti-inflammatory drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used for fever and inflammation, but avoid in dehydrated cats. Corticosteroids are contraindicated in acute infection due to immunosuppression, but may be used in chronic stromal keratitis or eosinophilic keratitis under antiviral coverage. Surgical intervention: In cases of corneal sequestrum, surgical removal may be necessary. For chronic rhinosinusitis, surgical debridement or turbinectomy may be considered, but is rarely curative. Dietary and nutritional requirements: Ensure adequate protein and calorie intake. Consider adding omega-3 fatty acids for anti-inflammatory effects. Physical rehabilitation: Not typically needed, but gentle nursing care is essential.

The prognosis for FHV-1 infection is generally good for adult cats with appropriate supportive care, with most recovering within 1-2 weeks. However, kittens and immunocompromised cats have a guarded prognosis, with mortality rates up to 30% in severe outbreaks. Chronic complications, such as chronic rhinosinusitis, corneal scarring, and eosinophilic keratitis, can occur in up to 20-30% of cats. Latent infection is lifelong, and recurrent episodes are common, especially during stress. Negative prognostic indicators include severe systemic signs, pneumonia, corneal perforation, and lack of response to treatment. With proper management, many cats can live a good quality of life, but chronic disease may require long-term therapy.

Follow-up care is essential for monitoring recovery and managing chronic complications. Re-check intervals: For acute cases, re-evaluate every 3-5 days until clinical signs resolve. For chronic cases, re-check every 2-4 weeks. Serial lab monitoring: CBC and biochemistry may be repeated if systemic disease is present. PCR can be repeated to monitor viral shedding, but is not routinely necessary. Repeat imaging: Thoracic radiographs if pneumonia was present, and nasal CT if chronic rhinitis. Dose-titration: Adjust antiviral doses based on renal function (famciclovir requires dose reduction in renal impairment). Long-term management: For cats with recurrent episodes, minimize stress, provide a stable environment, and consider lysine supplementation. Vaccination is recommended for all cats, with boosters every 1-3 years. In multi-cat environments, isolate infected cats and implement strict hygiene protocols.

Pearls: 1) Dendritic corneal ulcers are pathognomonic for FHV-1; perform fluorescein staining in any cat with conjunctivitis. 2) Famciclovir is the most effective systemic antiviral; use at 40-90 mg/kg PO q8h. 3) Topical cidofovir is effective for ocular disease and has less systemic toxicity. 4) Lysine may be beneficial as a prophylactic, but its efficacy is debated. 5) Stress reduction is key to preventing reactivation. Pitfalls: 1) Do not use corticosteroids in acute infection, as they can worsen disease. 2) Avoid using topical atropine in cats with corneal ulcers, as it can cause severe xerophthalmia. 3) Do not rely on serology for diagnosis, as titers are not diagnostic. 4) PCR can be falsely negative if sampling is not done during active shedding; repeat if suspicion is high. 5) Do not overlook secondary bacterial infections, which are common and require appropriate antibiotics.

Antiviral drugs: Famciclovir: 40-90 mg/kg PO q8h for 7-14 days; adjust dose in renal impairment (e.g., 40 mg/kg q12h if creatinine clearance < 50 ml/min). Topical cidofovir 0.5% ophthalmic solution: 1 drop in each affected eye q12h for 7-14 days. Ganciclovir 0.15% ophthalmic gel: 1 drop q8h. Idoxuridine 0.1% ophthalmic solution: 1 drop q6h. Lysine: 250-500 mg/cat PO q12h; may be used long-term. Antibiotics (for secondary bacterial infections): Amoxicillin-clavulanate: 20 mg/kg PO q12h for 7-14 days. Doxycycline: 5-10 mg/kg PO q12h for 7-14 days (avoid in kittens < 4 months due to tooth discoloration). Azithromycin: 5-10 mg/kg PO q24h for 3-5 days. Ophthalmic antibiotics: Oxytetracycline ointment: apply q8h. Erythromycin ointment: apply q8h. Anti-inflammatory drugs: NSAIDs (e.g., meloxicam 0.05 mg/kg PO q24h for 3-5 days) for fever and inflammation, but use with caution in dehydrated cats. Corticosteroids (e.g., prednisolone 1-2 mg/kg PO q24h) are contraindicated in acute infection, but may be used in chronic stromal keratitis or eosinophilic keratitis with concurrent antiviral therapy. Supportive care: Fluid therapy: Lactated Ringer's solution at 40-60 ml/kg/day IV or SC. Nutritional support: Esophagostomy tube feeding with a high-calorie diet. Nebulization with saline: 10-15 minutes q8h. Mucolytics (e.g., N-acetylcysteine 50 mg/kg PO q12h) may be used for chronic rhinitis, but evidence is limited.

Key studies and consensus guidelines: 1) The 2013 AAFP Feline Vaccination Advisory Panel Report recommends FHV-1 vaccination as core for all cats, with boosters every 3 years. 2) A study by Malik et al. (2009) demonstrated that famciclovir at 40-90 mg/kg PO q8h is effective in reducing clinical signs and viral shedding in experimentally infected cats. 3) A randomized controlled trial by Thomasy et al. (2011) showed that topical cidofovir 0.5% was superior to placebo in treating herpetic keratitis. 4) A meta-analysis by Maggs et al. (2003) found that lysine supplementation may reduce viral replication, but clinical efficacy is inconsistent. 5) The ABCD (European Advisory Board on Cat Diseases) guidelines recommend PCR as the diagnostic test of choice, and emphasize the importance of stress reduction in managing latent infection. 6) A study by Gaskell et al. (2007) on the epidemiology of FHV-1 in shelters highlighted the role of overcrowding and stress in outbreaks. 7) Research by Gould et al. (2012) on the pathogenesis of chronic rhinitis in cats with FHV-1 suggests that persistent inflammation and secondary bacterial infection contribute to chronic disease. 8) A consensus statement from the International Society of Feline Medicine (ISFM) on feline respiratory disease recommends a multimodal approach to treatment, including antiviral therapy, supportive care, and management of secondary infections.